Stratified Therapy on Pediatric AAGN
Summary
Clinical information of children with ANCA-associated nephritis admitted to Children's Hospital Affiliated to Chongqing Medical University and partner centers from January 1, 2023 to December 31, 2023 was collected: To evaluate and compare the differences in survival, renal outcomes, and adverse reactions in children with ANCA-associated nephritis given different interventions according to the revised PARRG risk stratification, and to evaluate the superiority of ANCA-associated nephritis given according to the revised PARRG risk stratification. (2) To evaluate the efficacy and safety of glucocorticoid combined with rituximab and cyclophosphamide as induction regimen in high-risk group and glucocorticoid combined with rituximab as induction regimen in children with ANCA-associated nephritis (AAGN) in low and middle risk group based on PARRG risk stratification
Timeline
- Start
- 2023-01-01
- Primary completion
- 2023-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 7.5 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 10 mg/kg | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | 15 mg/kg | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | 30 mg/kg | Intravenous |
| Subject | Prednisone | Other / unclassified | 1.5 mg/kg | Oral |
| Subject | Prednisone | Other / unclassified | 2 mg/kg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |